The 1-year ( OS : 74.2 % vs. 50.0 % , 95 % CI : 63.6-84 .8 % vs. 37.8-62 .2 , p = 0.002 ) , 2-year ( OS : 53.0 % vs. 30.3 % , 95 % CI : 40.8-65 .2 % vs. 19.1-41 .5 % , p = 0.002 ) , 3-year ( OS : 42.4 % vs. 24.2 % , 95 % CI : 30.4-54 .4 % vs. 13.8-34 .6 % , p = 0.005 ) and median overall and progression-free survivals of arm 1 patients were significantly higher than those of arm 2 .